Frédérique Penault‐Llorca

48.7k total citations · 7 hit papers
335 papers, 18.7k citations indexed

About

Frédérique Penault‐Llorca is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Frédérique Penault‐Llorca has authored 335 papers receiving a total of 18.7k indexed citations (citations by other indexed papers that have themselves been cited), including 209 papers in Oncology, 150 papers in Cancer Research and 90 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Frédérique Penault‐Llorca's work include Breast Cancer Treatment Studies (107 papers), HER2/EGFR in Cancer Research (86 papers) and Cancer Genomics and Diagnostics (49 papers). Frédérique Penault‐Llorca is often cited by papers focused on Breast Cancer Treatment Studies (107 papers), HER2/EGFR in Cancer Research (86 papers) and Cancer Genomics and Diagnostics (49 papers). Frédérique Penault‐Llorca collaborates with scholars based in France, United States and Italy. Frédérique Penault‐Llorca's co-authors include Fátima Cardoso, Philip Poortmans, Elżbieta Senkus, S. Kyriakides, Sophia Zackrisson, Shinji Ohno, Nadia Harbeck, Giuseppe Viale, Nehmat Houssami and Javier Cortés and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Frédérique Penault‐Llorca

320 papers receiving 18.3k citations

Hit Papers

Breast cancer 2006 2026 2012 2019 2019 2006 2019 2015 2020 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Breast cancer
    2019 2.0k citations Frédérique Penault‐Llorca, Javier Cortés et al. profile →
  2. KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
    2006 1.7k citations Frédérique Penault‐Llorca et al. profile →
  3. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2019 1.4k citations Fátima Cardoso, S. Kyriakides et al. Annals of Oncology profile →
  4. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2015 1.2k citations Elżbieta Senkus, S. Kyriakides et al. Annals of Oncology profile →
  5. HER2-Low Breast Cancer: Pathological and Clinical Landscape
    2020 490 citations Paolo Tarantino, Erika Hamilton et al. Journal of Clinical Oncology profile →
  6. HER2 testing in gastric cancer: a practical approach
    2012 448 citations Josef Rüschoff, Wedad Hanna et al. Modern Pathology profile →
  7. Implementing TMB measurement in clinical practice: considerations on assay requirements
    2019 247 citations Nicola Normanno, Frédérique Penault‐Llorca et al. ESMO Open profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Frédérique Penault‐Llorca France 57 10.8k 7.1k 5.4k 4.4k 3.2k 335 18.7k
Naoto T. Ueno United States 72 11.0k 1.0× 6.5k 0.9× 5.6k 1.0× 3.7k 0.8× 2.0k 0.6× 547 20.4k
Wedad Hanna Canada 45 10.6k 1.0× 7.6k 1.1× 4.6k 0.9× 3.2k 0.7× 3.5k 1.1× 156 17.0k
Michael Untch Germany 65 12.6k 1.2× 10.1k 1.4× 3.7k 0.7× 3.7k 0.8× 3.9k 1.2× 542 19.7k
Sandra M. Swain United States 66 15.4k 1.4× 7.2k 1.0× 5.1k 1.0× 4.8k 1.1× 4.9k 1.5× 337 23.4k
Masakazu Toi Japan 68 10.8k 1.0× 6.9k 1.0× 8.0k 1.5× 6.1k 1.4× 2.2k 0.7× 666 21.5k
Emad A. Rakha United Kingdom 68 9.4k 0.9× 9.4k 1.3× 8.1k 1.5× 2.7k 0.6× 2.2k 0.7× 494 20.5k
John M.S. Bartlett United Kingdom 60 10.5k 1.0× 7.0k 1.0× 6.2k 1.2× 3.7k 0.8× 4.1k 1.3× 310 18.8k
Nicola Normanno Italy 63 10.5k 1.0× 4.5k 0.6× 8.4k 1.6× 5.6k 1.3× 1.9k 0.6× 362 18.5k
Ana M. González-Angulo United States 83 15.2k 1.4× 11.4k 1.6× 8.9k 1.7× 5.2k 1.2× 2.7k 0.9× 281 25.2k
Bryan T. Hennessy Ireland 59 9.0k 0.8× 6.4k 0.9× 9.7k 1.8× 3.0k 0.7× 1.6k 0.5× 266 19.8k

Countries citing papers authored by Frédérique Penault‐Llorca

Since Specialization
Citations

This map shows the geographic impact of Frédérique Penault‐Llorca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frédérique Penault‐Llorca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frédérique Penault‐Llorca more than expected).

Fields of papers citing papers by Frédérique Penault‐Llorca

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frédérique Penault‐Llorca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frédérique Penault‐Llorca. The network helps show where Frédérique Penault‐Llorca may publish in the future.

Co-authorship network of co-authors of Frédérique Penault‐Llorca

This figure shows the co-authorship network connecting the top 25 collaborators of Frédérique Penault‐Llorca. A scholar is included among the top collaborators of Frédérique Penault‐Llorca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frédérique Penault‐Llorca. Frédérique Penault‐Llorca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Valenza, Carmine, Dario Trapani, François‐Clément Bidard, et al.. (2024). Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access?. ESMO Open. 9(9). 103701–103701. 2 indexed citations
2.
Seegers, Valérie, Guillaume Rousseau, Ke Zhou, et al.. (2023). COVID-19 Infection despite Previous Vaccination in Cancer Patients and Healthcare Workers: Results from a French Prospective Multicenter Cohort (PAPESCO-19). Cancers. 15(19). 4777–4777. 2 indexed citations
3.
Seegers, Valérie, Guillaume Rousseau, Ke Zhou, et al.. (2022). COVID-19 Vaccination Campaign in Cancer Patients and Healthcare Workers-Results from a French Prospective Multicenter Cohort (PAPESCO-19). Cancers. 14(22). 5547–5547. 2 indexed citations
4.
Penault‐Llorca, Frédérique, Keith M. Kerr, Pilar Garrido, et al.. (2022). Expert opinion on NSCLC small specimen biomarker testing — Part 1: Tissue collection and management. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 481(3). 335–350. 29 indexed citations
5.
Collet, L., Julien Péron, Frédérique Penault‐Llorca, et al.. (2022). PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers. Cancers. 14(3). 599–599. 7 indexed citations
6.
Tarantino, Paolo, Erika Hamilton, Sara M. Tolaney, et al.. (2020). HER2-Low Breast Cancer: Pathological and Clinical Landscape. Journal of Clinical Oncology. 38(17). 1951–1962. 490 indexed citations breakdown →
7.
Idrissou, Mouhamed, Isabelle Lebert, Anna Sánchez, et al.. (2020). Digging Deeper into Breast Cancer Epigenetics: Insights from Chemical Inhibition of Histone Acetyltransferase TIP60 In Vitro. OMICS A Journal of Integrative Biology. 24(10). 581–591. 3 indexed citations
8.
Senkus, Elżbieta, S. Kyriakides, Frédérique Penault‐Llorca, et al.. (2013). Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 24. vi7–vi23. 350 indexed citations
9.
Franchet, Camille, Thomas Filleron, Anne Cayre, et al.. (2013). Instant‐quality fluorescence in‐situ hybridization as a new tool for HER2 testing in breast cancer: a comparative study. Histopathology. 64(2). 274–283. 9 indexed citations
10.
Chêne, Geneviève, Andréï Tchirkov, J Dauplat, et al.. (2013). Early Telomere Shortening and Genomic Instability in Tubo-Ovarian Preneoplastic Lesions. Clinical Cancer Research. 19(11). 2873–2882. 31 indexed citations
11.
Rüschoff, Josef, Wedad Hanna, Michael Bilous, et al.. (2012). HER2 testing in gastric cancer: a practical approach. Modern Pathology. 25(5). 637–650. 448 indexed citations breakdown →
12.
Penault‐Llorca, Frédérique & Laurent Arnould. (2010). [Adjuvant breast cancer: which clinical and pathological characteristics in 2007?].. PubMed. 97(12). 1421–6. 5 indexed citations
13.
Léary, Alexandra, Wedad Hanna, Marc J. van de Vijver, et al.. (2009). Value and Limitations of Measuring HER-2 Extracellular Domain in the Serum of Breast Cancer Patients. Journal of Clinical Oncology. 27(10). 1694–1705. 57 indexed citations
14.
Penault‐Llorca, Frédérique. (2007). Thérapeutiques ciblées : problématique de la détection de la cible. Bulletin du Cancer. 94(6). 245–248. 1 indexed citations
15.
Arnould, Laurent, Frédérique Penault‐Llorca, L. Benoît, et al.. (2006). Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. British Journal of Cancer. 94(2). 259–267. 424 indexed citations
16.
Penault‐Llorca, Frédérique, Xavier Durando, & Jacques‐Olivier Bay. (2003). [Prognostic value of epidermal growth factor receptor].. PubMed. 90 Spec No. S192–6. 2 indexed citations
17.
Penault‐Llorca, Frédérique, Anne Cayre, Florence Mishellany, et al.. (2003). Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. International Journal of Oncology. 22(6). 1319–25. 64 indexed citations
18.
Penault‐Llorca, Frédérique, Xavier Durando, & Jacques‐Olivier Bay. (2003). Valeur pronostique du récepteur du facteur de croissance épidermique.. Bulletin du Cancer. 90. 1 indexed citations
19.
Penault‐Llorca, Frédérique, et al.. (1994). The heregulin gene can be included in the 8p12 amplification unit in human breast cancer. Genes Chromosomes and Cancer. 11(1). 66–69. 6 indexed citations
20.
Penault‐Llorca, Frédérique, José Adélaı̈de, Gilles Houvenaeghel, et al.. (1994). Optimization of immunohistochemical detection of ERBB2 in human breast cancer: Impact of fixation. The Journal of Pathology. 173(1). 65–75. 107 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Naoto T. Ueno Breakdown of academic impact, for papers by Wedad Hanna Breakdown of academic impact, for papers by Michael Untch Breakdown of academic impact, for papers by Sandra M. Swain Breakdown of academic impact, for papers by Masakazu Toi Breakdown of academic impact, for papers by Emad A. Rakha Breakdown of academic impact, for papers by John M.S. Bartlett Breakdown of academic impact, for papers by Nicola Normanno Breakdown of academic impact, for papers by Ana M. González-Angulo Breakdown of academic impact, for papers by Bryan T. Hennessy
Rankless by CCL
2026